Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Preferred Stock Liabilities (2020 - 2021)

Climb Bio filings provide 2 years of Preferred Stock Liabilities readings, the most recent being $152.8 million for Q2 2021.

  • Quarterly Preferred Stock Liabilities rose 464.42% to $152.8 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $152.8 million through Jun 2021, up 464.42% year-over-year, with the annual reading at $46.6 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $152.8 million in Q2 2021 for Climb Bio, up from $92.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $152.8 million in Q2 2021 and bottomed at $27.1 million in Q2 2020.